Introduction {#s01}
============

Although most tissue resident macrophage populations are initially populated by primordial yolk sac--derived macrophages ([@bib5]; [@bib29]), some are replaced with cells derived from fetal monocytes or hematopoietic stem cells, leading to either complete replacement of yolk sack--derived macrophages or mixed populations that are dominated by cells of the fetal monocyte or hematopoietic stem cell lineage ([@bib24]; [@bib34]; [@bib64]). Microglia, however, are a notable exception to this rule, and under homeostatic conditions, they self-renew from the original yolk sac lineage throughout the life of the animal ([@bib4]; [@bib23]; [@bib24]; [@bib12]; [@bib34]; [@bib64]).

Monocytes do not enter the healthy brain but are seen within the brain parenchyma under certain pathological conditions, where their contribution to central nervous system (CNS) pathology is highly debated ([@bib15]; [@bib39]; [@bib18]; [@bib58]; [@bib74]; [@bib38]; [@bib69]; [@bib72]). Further, the conditions required for macrophage engraftment into the CNS parenchyma are not well understood. However, hematopoietic cells readily engraft the brain after lethal whole-body irradiation and bone marrow transplantation (BMT), often assumed to be secondary to blood--brain barrier (BBB) opening after irradiation ([@bib57]; [@bib55]).

These peripherally derived brain-engrafting macrophages (beMφs) were initially noted to spatially replace microglia, tiling with resident microglia, and to develop ramifications similar to those of microglia ([@bib57]; [@bib55]). These findings led to the hypothesis that hematopoietic-derived macrophages are capable of differentiating into true microglia upon engraftment. Indeed, several groups have found that the tissue environment directs macrophage differentiation, transcriptomes, and function ([@bib45]; [@bib28]; [@bib9]; [@bib62]; [@bib70]), supporting the concept that the brain environment may be sufficient to drive differentiation of peripheral-derived microglia.

In the context of clinical implications, it has been shown that macrophage engraftment after BMT is beneficial in lysosomal storage disease ([@bib71]; [@bib41], [@bib42]; [@bib56]), a mouse model of obsessive-compulsive disorder ([@bib17]), and some mouse models of neurodevelopmental disorders ([@bib21]; [@bib35]). However, the role of beMφs in other pathologies, such as CNS injury, Alzheimer's disease, and amyotrophic lateral sclerosis, remains a topic of debate ([@bib58]).

Major questions about beMφs remain. What are the conditions necessary for engraftment into the brain, and is irradiation required for engraftment? Do beMφs alter brain function? Do beMφs become true microglia, or are they an independent class of resident brain macrophages that exists under defined conditions?

Results {#s02}
=======

Partial microglia depletion leads to beMφ engraftment independent of irradiation, without affecting behavior {#s03}
------------------------------------------------------------------------------------------------------------

We first set out to test the hypothesis that creation of a brain niche by chronic microglia depletion is sufficient to drive beMφ engraftment, independent of irradiation. To deplete microglia chronically, we used *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice fed tamoxifen chow to chronically excise *Csf1r* (the gene encoding colony-stimulating factor 1 receptor, which is critical for microglia survival) from cells expressing *Cx3cr1*, which in the brain is restricted to microglia ([@bib51]; [@bib30]; [@bib75]).

Before analyzing the brain, we assessed the peripheral immune system, which contains many cells that express *Cx3cr1*. *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice treated with tamoxifen demonstrated chronic deficiency in Cx3cr1^+^ lamina propria intestinal macrophages (Fig. S1, A--C). Although Cx3cr1^lo/neg^Ly6C^hi^ monocytes did not experience significant changes upon tamoxifen treatment, Cx3cr1^hi^Ly6C^lo^ monocytes were severely depleted in these mice (Fig. S1, D--F), consistent with expression of Cre driven by the Cx3cr1 promoter.

We then moved on to analyze the brain. Although no differences were observed in microglia counts between *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* and *Cx3cr1^+/+^::Csf1r^Flox/Flox^* animals fed control chow (Fig. S2 A), 1 wk on a tamoxifen diet induced an ∼25% reduction of microglia throughout the brain, which was maintained for the duration of tamoxifen treatment (Fig. 1, A and B). When Csf1r levels were analyzed after 12 wk on a tamoxifen diet, both protein and gene expression were reduced, but not completely eliminated, as compared with Cre-negative controls ([Fig. 1 C](#fig1){ref-type="fig"} and Fig. S2, B and C), consistent with partial microglia depletion. To help explain why microglia were only partially depleted, we immunostained for Ki67 and assessed the incorporation of BrdU. We found that microglia were Ki67^+^ and BrdU^+^ in *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice, but not *Cx3cr1^+/+^::Csf1r^Flox/Flox^* mice, fed tamoxifen chow (Fig. S2, D and E). These data demonstrate that the microglia niche begins to proliferate in response to inducible *Csf1r* excision, suggesting that microglia loss is countered by proliferation of the remaining Csf1r-expressing microglia, or that signaling through another growth factor receptor is capable of driving microglia proliferation.

![**Partial microglia depletion leads to beM**φ **engraftment independent of irradiation. (A)** Representative images of Iba1^+^ microglia (red) after 4 wk of tamoxifen treatment in *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice and Cre-negative controls. Nuclei (DAPI) are shown in blue (*n* = 3 Cre^−^ and 4 Cre^+^ mice). Bar, 100 µm. **(B)** Deleting Csf1r from microglia results in ∼25% chronic reduction of microglia throughout the brain (*n* = 3--4 mice per group for each time point; representative of two experiments). **(C)** Gene expression by quantitative RT-PCR of CD115/Csf1r on sorted microglia (*n* = 3 per group; two-tailed Student's *t* test, \*\*, P \< 0.01; performed once). **(D)** Quantification of Evans blue dye in brains of *Cx3cr1^+/+^::Csf1r^flox/flox^* and *Cx3cr1^CreER/+^::Csf1r^flox/flox^* mice fed tamoxifen diet for 15 wk (*n* = 4 and 3 mice per group, two-tailed Student's *t* test, not significant; performed once). **(E)** Top: Injection strategy for GFP^+^ monocytes. Bottom: Representative images of GFP^+^ beMφs (green) infiltrating adjacent to a lateral ventricle 1 and 9 wk after the last monocyte injection. All brain macrophages (resident microglia and beMφs) are positive for Iba1 (red). Images are representative of *n* = 3 mice (representative of two experiments). Bar, 200 µm. **(F)** Left: Cartoon of parabiotic pairings. UBC-GFP mice were paired to *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice and Cre-negative controls. After 12 wk of tamoxifen treatment, blood was analyzed by flow cytometry (middle), and brains were analyzed by immunohistochemistry (right). Although the percentage of GFP^+^ cells in the blood was similar between *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice and Cre-negative controls, GFP^+^ beMφs (green) were only found in Cre-positive mice. All brain macrophages, including microglia, were Iba1 positive (red). Images/data are representative of *n* = 3 mice per group. Bars, 200 µm. **(G)** Strategy to assess engraftment of beMφs after BMT using lead to shield the head (i). Representative images of beMφs (green) after 12 wk on tamoxifen (ii). All macrophages, including microglia, are Iba1^+^ (red), whereas beMφs are also GFP^+^ (green). Bar, 500 µm. LV, lateral ventricle. Illustrations of beMφ engraftment after 12 wk on tamoxifen (iii). Silhouettes of brain sections were generated on actual brain slices and beMφs locations were marked with a green dot. Each dot represents a single GFP^+^Iba1^+^ beMφ. Images are representative of *n* = 3--6 mice per group (representative of two independent experiments). **(H--L)** No differences in behavior were observed in mice containing beMφs (Cre+). *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice and Cre-negative controls underwent BMT with head shielding. After recovery, mice were treated with tamoxifen for 12 wk and then placed back on a regular diet for 4 wk before behavioral testing. Mice were tested on the plus maze (H; not significant, two-tailed Student's *t* test; *n* = 24, 23; pooled data from two independent cohorts), open field (I; not significant, two-tailed Student's *t* test; *n* = 24, 23; pooled data from two independent cohorts), three-chamber social assay (J; not significant for genotype and \*, P \< 0.05 for social variable, two-way repeated measures ANOVA with Sidak's post hoc; *n* = 15; pooled data from two independent experiments), rotarod (K; not significant for genotype, two-way repeated measures ANOVA; *n* = 9, 8; experiment performed once), and water maze (L; not significant for acquisition, two-way repeated measures ANOVA and not significant for probe trial, two-tailed Student's *t* test; *n* = 9, 8; performed once). **(M)** Quantification of brain macrophages from mice in behavior assays by flow cytometry. Mice were analyzed after behavior assays were complete, at least 8 wk after they had been placed back on regular diet. Brains of Cre-positive mice contained 48.2% ± 14.2 SEM beMφs (GFP^+^) out of total CD45/CD11b^+^ cells (not significant, two-tailed Student's *t* test; *n* = 3 samples per cell type with 3--4 mice pooled per sample; performed once). Error bars represent ±SEM.](JEM_20180247_Fig1){#fig1}

Together, these data demonstrated that inducible deletion of *Csf1r* in microglia leads to chronic, partial microglia loss, leaving a partially unfilled niche. We could therefore use this model to test whether the presence of a niche (formed without irradiation) that cannot be filled by microglia, could allow beMφ engraftment. Importantly, we did not detect increased BBB permeability in tamoxifen-treated Cre-positive as compared with Cre-negative mice ([Fig. 1 D](#fig1){ref-type="fig"}). We first injected ∼95% pure Ly6C^hi^CD115^+^ sorted bone marrow monocytes expressing GFP (Fig. S2 F) intravenously into *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice on a tamoxifen diet. Starting 1 wk after tamoxifen, mice were given three weekly intravenous injections of GFP^+^ monocytes. Mice were analyzed 1 or 9 wk after the final monocyte transfer (4 or 12 wk after tamoxifen initiation). The brains of Cre-positive animals contained ramified GFP^+^ beMφs ([Fig. 1 E](#fig1){ref-type="fig"}), whereas none were observed in brains of Cre-negative mice (Fig. S2 G). These results supported the hypothesis that in the context of chronic microglia deficiency (and without CNS irradiation, infection, or BBB compromise), circulating monocytes can engraft into the CNS and persistently fill the available niche created by depleted microglia, as cells were still present 9 wk after the final cell transfer.

It is possible that sorted bone marrow monocytes possess a unique ability to engraft the CNS that is not possessed by circulating blood monocytes. To confirm that circulating cells are capable of engrafting the CNS, we used parabiotic mice. Cre-negative or Cre-positive mice were parabiotically joined to UBC-GFP mice and placed on a tamoxifen diet for 12 wk. As expected, Cre-negative mice had no detectable GFP^+^ cells in their brains, whereas Cre-positive mice contained GFP^+^ ramified beMφs in the parenchyma ([Fig. 1 F](#fig1){ref-type="fig"}). Because the bone marrow niche remains undisturbed in parabiosis, these results provide evidence that circulating monocytes (or, at a minimum, circulating leukocytes) indeed possess the ability to engraft the brain and become beMφs when the microglia-vacant niche is present.

Although monocyte transfer and parabiosis demonstrated that beMφs can and will engraft the microglia-depleted brain without irradiation, these experiments did not reveal the potential extent of beMφ engraftment. To understand the full extent of peripheral-derived engraftment into the CNS in tamoxifen-treated *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice, we decided to completely replace the peripheral immune system with GFP-expressing cells. To this end, we performed BMT with lead shielding of the head, a well-established technique to prevent beMφ engraftment after BMT ([@bib13], [@bib14]; [@bib61]; [@bib63]; [@bib21]). 5 wk after BMT, nearly every circulating immune cell (except T cells, which is a known phenomenon; [@bib11]) was GFP^+^, including nearly 100% of monocytes (Fig. S2, H--M).

We then assessed beMφ engraftment at 2, 4, or 12 wk after tamoxifen. We could only detect rare GFP^+^Iba1^+^ ramified beMφs after 2 wk, primarily in circumventricular regions (Fig. S3, A--C), but after 4 wk, the circumventricular regions of these mice had considerable engraftment of beMφs (Fig. S3, A--D). Interestingly, we observed that although GFP^+^ cells could be found in the choroid plexus and ventricle walls of all mice, ramified GFP^+^Iba1^+^ beMφs were only present in the brain parenchyma in *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice (Fig. S3 D). After 12 wk, we found GFP^+^Iba1^+^ macrophage engraftment throughout the brains of *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* animals, as opposed to their Cre-negative counterparts, in which no ramified GFP^+^ cells were observed anywhere in the brain parenchyma ([Figs. 1 G](#fig1){ref-type="fig"} and S3 C). Furthermore, if we irradiated the entire mouse (including the head) beMφ engraftment into *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice was greatly accelerated compared with Cre-negative controls (Fig. S3, E and F). This suggests that although CNS irradiation induces beMφ engraftment, this is substantially enhanced by impairment of microglia self-renewal by deletion of *Csf1r*.

We next set out to interrogate whether beMφ affect brain function using a battery of behavioral assays. Head-covered BMT was performed in *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* and *Cx3cr1^+/+^::Csf1r^Flox/Flox^* mice as described above, and mice were fed a tamoxifen diet for 12 wk, followed by 4 wk of control chow to eliminate the potential effects of tamoxifen on behavior. We found no difference in any behavioral assays tested, such as elevated plus maze ([Fig. 1 H](#fig1){ref-type="fig"}), open field ([Fig. 1 I](#fig1){ref-type="fig"}), sociability ([Fig. 1 J](#fig1){ref-type="fig"}), rotarod ([Fig. 1 K](#fig1){ref-type="fig"}), or Morris water maze ([Fig. 1 L](#fig1){ref-type="fig"}). Importantly, we found that Cre-positive mice had a mean of 48% GFP^+^ beMφs out of all CNS macrophages/microglia at the conclusion of behavioral testing, at which point mice had been on control chow for a minimum of 8 wk ([Fig. 1 M](#fig1){ref-type="fig"}). Together, these results suggest that even with significant microglia replacement by beMφs, overall brain function is not affected.

beMφs are transcriptionally distinct from microglia {#s04}
---------------------------------------------------

We next set out to test the hypothesis that beMφs are an independent class of brain macrophage that maintains a unique functional and transcriptomic profile. To this end, we decided to perform RNA sequencing on beMφ and microglia in three unique models of beMφ engraftment. First, we sorted live CD45^+^CD11b^+^ and either GFP-negative (microglia) or GFP-positive (beMφ) cells from the same brains of tamoxifen-treated *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice. Microglia and beMφ clustered strongly by cell type, with cell type accounting for 96% of the transcriptional variance ([Fig. 2 A](#fig2){ref-type="fig"}). Compared with microglia, beMφs had 1,512 differentially up-regulated and 1,598 differentially down-regulated genes ([Fig. 2 B](#fig2){ref-type="fig"} and Table S1).

![**beMφs are a transcriptionally distinct cell type. (A)** PCA plot and heatmap of distance between samples for beMφs and microglia in the *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* model with head-covered BMT and tamoxifen treatment. Mice were treated with tamoxifen for 12 wk, followed by a minimum of 8 wk on control chow (each dot represents a pooled sample from at least three mice). **(B)** Differentially expressed genes (adjusted P \< 0.05) between beMφs and microglia in the *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* model with head-covered BMT and tamoxifen treatment. The values are standardized rlog-transformed values across samples. **(C)** PCA plot and heatmap of distance between samples for the beMφs and microglia when using traditional BMT (each dot represents a pooled sample from at least three mice). **(D)** Differentially expressed genes (adjusted P \< 0.05) between beMφs and microglia when using traditional BMT. The values are standardized rlog-transformed values across samples. **(E)** Strategy for achieving beMφ engraftment using BMT with or without head covering and PLX5622 treatment. **(F)** Representative images and quantification of GFP^+^ beMφs in mice treated as in E. Bar, 200 µm. HC, head covered; WBI, whole-body irradiation. **(G)** PCA plot and heatmap of distance between samples for beMφs and microglia when using BMT/PLX5622 (each dot represents a pooled sample from at least three mice). **(H)** Differentially expressed genes (adjusted P \< 0.05) between beMφs and microglia when using BMT/PLX5622. The values are standardized rlog-transformed values across samples.](JEM_20180247_Fig2){#fig2}

In our second model of beMφ engraftment, we replicated classic beMφ engraftment models by performing whole-body irradiation and BMT with UBC-GFP bone marrow. We then allowed cells to engraft and remain for 9 mo and sorted beMφs and microglia from the same brains. Again, we found that cell type accounted for the large majority of variance (97%; Fig. 2 C), and when compared with microglia, beMφs had a large number of differentially up-regulated (2,008) and differentially down-regulated genes (1,596; [Fig. 2 D](#fig2){ref-type="fig"} and Table S1).

Our third model was designed to take advantage of the synergistic effect on engraftment we had observed with the combination of CNS irradiation and *Csf1r* deletion in microglia (Fig. S3, E and F). Instead of *Csf1r* deletion using our genetic model, we used the *Csf1r* inhibitor PLX5622 in chow to eliminate the irradiation-damaged, yet still viable, microglia. Mice were given BMT with UBC-GFP bone marrow with or without head covering during irradiation, followed by 1 wk of recovery, 2 wk of chow containing PLX5622, and finally 6 wk of recovery on standard chow ([Fig. 2 E](#fig2){ref-type="fig"}). In this model, mice with head covering had minimal GFP^+^ beMφ engraftment and had effectively repopulated the CNS with endogenous microglia with minimal beMφ engraftment ([Fig. 2 F](#fig2){ref-type="fig"}), consistent with previously published data ([@bib23]). However, mice that had received whole-body irradiation demonstrated robust engraftment of GFP^+^ beMφ ([Fig. 2 F](#fig2){ref-type="fig"}), mimicking the synergistic effects of inducible deletion of *Csf1r* and whole-body irradiation with BMT in our previous experiments. Because of the robust level of engraftment in this model, we sorted GFP^+^ beMφs from whole-body--irradiated mice and GFP^−^ microglia from head-covered mice for RNA sequencing. We again found that cell type accounted for the large majority of transcriptional variance (92%; [Fig. 2 G](#fig2){ref-type="fig"}) and that when compared with microglia, beMφs had 829 differentially up-regulated and 1,275 differentially down-regulated genes ([Fig. 2 H](#fig2){ref-type="fig"} and Table S1).

beMφs are functionally distinct from microglia {#s05}
----------------------------------------------

To assess beMφ function in each of the three engraftment models, we used gene set variation analysis (GSVA; [@bib31]) to identify commonly enriched Gene Ontology Biological Process (GOBP) terms in beMφ versus microglia, and vice versa. There were 117 GOBP terms commonly enriched in all three beMφ datasets and 47 GOBP terms commonly enriched in all three microglia datasets (Table S2). Within these commonly enriched functional terms, several notable functions and themes were apparent. Consistently, beMφs were enriched for "regulation of wound healing, spreading of epidermal cells," as well as multiple functions for extracellular uptake, growth factor signaling and production, extracellular matrix interaction and migration, regulation of vasculogenesis, interactions with neurons and glia, lipid metabolism, and a large number of immunological processes ([Fig. 3 A](#fig3){ref-type="fig"} and Table S2). Microglia also demonstrated common functions for interaction with neurons and glia and lipid metabolism, but also notably had multiple functions related to neurotransmitters and steroids ([Fig. 3 B](#fig3){ref-type="fig"} and Table S2). These results suggest that although beMφs and microglia may have some similar functional themes, they are not functionally interchangeable cell types, supporting the hypothesis that these are two distinct populations of CNS macrophages.

![**beMφs and microglia maintain unique predicted functions in multiple experimental models. (A)** Selected beMφ Gene Ontology biological functions that are identified as enriched by GSVA in the *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* model with head-covered BMT and tamoxifen treatment, traditional BMT, and BMT/PLX5622 when compared with the microglia in the same experiment. The boxplots show the distribution of the −log10(FDR-adjusted p-value) of the corresponding functional term calculated for each of the three experiments. A complete list of functions commonly up-regulated in beMφs versus microglia in all datasets can be found in Table S2. **(B)** Selected microglia Gene Ontology biological functions that are identified as enriched by GSVA in the *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* model with head-covered BMT and tamoxifen treatment, traditional BMT, and BMT/PLX5622 when compared with beMφs in the same experiment. Boxplots show the distribution with mean of the −log10(FDR-adjusted p-value) of the corresponding functional term calculated for each of the three experiments. A complete list of functions commonly up-regulated in microglia versus beMφs in all datasets can be found in Table S2.](JEM_20180247_Fig3){#fig3}

Although our RNA-sequencing analysis suggested that microglia and beMφs are unique cell types, we decided to experimentally confirm differential response to stimuli. Using our system of BMT and PLX5622 treatment for beMφ engraftment, which allows substantial repopulation of microglia by beMφs, we first tested response to laser burn injury in live multiphoton imaging. Our results demonstrate that beMφs moved toward the laser burn faster than microglia ([Fig. 4 A](#fig4){ref-type="fig"}). We then assessed response to in vivo LPS injection. Mice were given i.p. LPS or saline injection, and the brains were collected for analysis 6 h later. Sholl analysis of Iba1 staining revealed that beMφs were less ramified than microglia and demonstrated no change in ramification after LPS, whereas microglia were significantly more ramified and demonstrated significant reduction in ramification after LPS ([Fig. 4 B](#fig4){ref-type="fig"}). Principal component analysis (PCA) of the corresponding RNA-sequencing dataset demonstrated distinct clustering of samples by cell type and treatment ([Fig. 4 C](#fig4){ref-type="fig"}). Differential expression (DE) analysis revealed a very large number of differentially expressed genes after LPS treatment (3,627 up-regulated and 4,910 down-regulated genes in beMφs as compared with microglia; [Fig. 4 D](#fig4){ref-type="fig"} and Table S1).

![**beM**φ**s have distinct morphology and response to stimuli compared with microglia. (A)** Representative images from two-photon in vivo imaging of microglia and beMφs responding to laser injury. Bar, 5 µm. Dots represent movement of processes over time. beMφ processes move more rapidly toward the injury site (Student's *t* test, \*\*, P \< 0.01; *n* = 3 mice; representative of two independent experiments). **(B)** Representative images of microglia and beMφs in response to LPS. All brain macrophages are Iba1^+^. Bar, 10 µm. Sholl analysis of microglia and beMφs 6 h after LPS injection (i.p.). beMφs are less complex than microglia and do not change complexity after LPS (two-way ANOVA P \< 0.0001 for an interaction between type of macrophages and branching over distance; \*\*\*, P \< 0.0001; \*\*, P \< 0.001; *n* = 60 microglia from three different mice per group; performed once). Error bars represent ±SEM. **(C)** PCA plots of RNA-sequencing transcriptional data from saline or LPS treated microglia and beMφs. **(D)** Differentially expressed genes (adjusted P \< 0.05) between saline- or LPS-treated microglia and beMφs. DE comparisons were made between saline- and LPS-treated samples separately to determine two lists of DE genes, which were combined and displayed for all samples in the heatmap. The values are standardized rlog-transformed values across samples.](JEM_20180247_Fig4){#fig4}

beMφs have a predictable genetic signature {#s06}
------------------------------------------

In our RNA-sequencing analysis of saline- or LPS-treated beMφs and microglia, we noted gene clusters that remained consistently differentially expressed between beMφs and microglia regardless of treatment ([Fig. 4 D](#fig4){ref-type="fig"}), suggesting that there are core genetic signatures that may be used to define and identify beMφs versus microglia. To this end, we generated genetic signatures for beMφs and microglia by first taking the commonly up-regulated genes among all three of the models of beMφ engraftment. For the beMφ signature, we then refined it by eliminating genes that were differentially expressed between peripheral myeloid cells and microglia in an RNA-sequencing study performed by [@bib45]; the goal of this refinement was to include only core genes that define beMφs versus microglia and not other myeloid cells versus microglia. For the microglia signature, we refined the signature using the study by [@bib45] by only including genes that were commonly unique to microglia in their study and to the microglia in our datasets. Finally, both signatures were refined by eliminating all genes that were not included in functionally enriched terms, thereby creating "functional" genetic signatures. This process created a 52-gene microglia signature (Mg-52; [Fig. 5 A](#fig5){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}) and a 50-gene beMφ signature (beMφ-50; [Fig. 5 A](#fig5){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}).

![**beMφs have a predictable genetic signature distinct from microglia. (A)** Schematic showing how the Mg-52 and beMφ-50 signatures were generated by intersecting differentially expressed genes between beMφs and microglia (fold change \> 1.5 and adjusted P \< 0.05) from the *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* model with head-covered BMT and tamoxifen treatment, traditional BMT, and BMT/PLX5622 RNA-sequencing datasets in this study and the myeloid cells in [@bib45]. **(B and C)** Representative images of brains from mice 9 mo after BMT (*n* = 4 mice per group; performed once). Bars, 50 µm. Donor bone marrow was from a transgenic mouse that expresses GFP under a UBC promoter. beMφs (green, GFP^+^) express Iba1 (B), but not P2ry12 (C). **(D)** Heatmap of the Mg-52 and beMφ-50 in the *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* model with head-covered BMT and tamoxifen treatment, traditional BMT, and BMT/PLX5622 RNA-sequencing datasets. The values are standardized rlog-transformed values across samples. **(E)** Overlap of the Mg-52 and beMφ-50 in the microglia developmental stages from [@bib54]. **(F)** Enrichment of the Mg-52 and beMφ-50 signatures in various cell types. Axes represent the value of the CAMERA test statistic for each signature (beMφs over microglia), which is used to calculate the corrected p-value (FDR corrected). Samples falling outside of the gray area indicate a statistically significant (FDR \<0.001) enrichment of the signature. Samples falling to the left of the gray area demonstrate enrichment for the signature in microglia as compared with the tested cell type. Samples falling to the right of the gray area demonstrate enrichment for the signature in the tested cell type as compared with microglia. Statistics can be found in [Table 4](#tbl4){ref-type="table"}. **(G)** Heatmap of the Mg-52 and beMφ-50 signatures in the Immgen microarray dataset. Values are standardized rlog-transformed values across samples. **(H and I)** Heatmaps of the Mg-52 and beMφ-50 signatures in beMφs and microglia in [@bib12] (H) and BMT/PLX5622 cells in mice treated with LPS (I); neither dataset was used in the generation of the signatures*.* The values are standardized rlog-transformed values across samples. **(J)** Enrichment of the Mg-52 and beMφ-50 signatures in induced pluripotent stem cell--derived microglia-like cells and BM Macs co-cultured with neurons from [@bib67]. The enrichment method is the same as described in F. Statistics can be found in [Table 4](#tbl4){ref-type="table"}.](JEM_20180247_Fig5){#fig5}

###### List of genes in the Mg-52 signature

  Symbol       Ensembl              Entrez   Name
  ------------ -------------------- -------- -----------------------------------------------------------------------------------------------
  *Abhd6*      ENSMUSG00000025277   66082    Abhydrolase domain containing 6
  *Adamts1*    ENSMUSG00000022893   11504    A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 1
  *Adgrg1*     ENSMUSG00000031785   14766    Adhesion G protein--coupled receptor G1
  *Adora3*     ENSMUSG00000000562   11542    Adenosine A3 receptor
  *Arhgap5*    ENSMUSG00000035133   11855    Rho GTPase-activating protein 5
  *Atp2c1*     ENSMUSG00000032570   235574   ATPase, Ca^2+^ sequestering
  *Atp6v0a2*   ENSMUSG00000038023   21871    ATPase, H+ transporting, lysosomal V0 subunit A2
  *Atp8a2*     ENSMUSG00000021983   50769    ATPase, aminophospholipid transporter-like, class I, type 8A, member 2
  *Bin1*       ENSMUSG00000024381   30948    Bridging integrator 1
  *Capn3*      ENSMUSG00000079110   12335    Calpain 3
  *Cd34*       ENSMUSG00000016494   12490    CD34 antigen
  *Cd81*       ENSMUSG00000037706   12520    CD81 antigen
  *Col27a1*    ENSMUSG00000045672   373864   Collagen, type XXVII, alpha 1
  *Commd8*     ENSMUSG00000029213   27784    COMM domain containing 8
  *Cst3*       ENSMUSG00000027447   13010    Cystatin C
  *Ctsl*       ENSMUSG00000021477   13039    Cathepsin L
  *Daglb*      ENSMUSG00000039206   231871   Diacylglycerol lipase, beta
  *Ecscr*      ENSMUSG00000073599   68545    Endothelial cell surface--expressed chemotaxis and apoptosis regulator
  *Entpd1*     ENSMUSG00000048120   12495    Ectonucleoside triphosphate diphosphohydrolase 1
  *Erf*        ENSMUSG00000040857   13875    Ets2 repressor factor
  *Fchsd2*     ENSMUSG00000030691   207278   FCH and double SH3 domains 2
  *Fscn1*      ENSMUSG00000029581   14086    Fascin actin-bundling protein 1
  *Gcnt1*      ENSMUSG00000038843   14537    Glucosaminyl (*N*-acetyl) transferase 1, core 2
  *Hexb*       ENSMUSG00000021665   15212    Hexosaminidase B
  *Il6st*      ENSMUSG00000021756   16195    Interleukin 6 signal transducer
  *Kcnd1*      ENSMUSG00000009731   16506    Potassium voltage-gated channel, Shal-related family, member 1
  *Kcnk6*      ENSMUSG00000046410   52150    Potassium inwardly rectifying channel, subfamily K, member 6
  *Ldhb*       ENSMUSG00000030246   16832    Lactate dehydrogenase B
  *Lpcat3*     ENSMUSG00000004270   14792    Lysophosphatidylcholine acyltransferase 3
  *Med12l*     ENSMUSG00000056476   329650   Mediator complex subunit 12-like
  *Numb*       ENSMUSG00000021224   18222    Numb homologue (*Drosophila*)
  *P2ry12*     ENSMUSG00000036353   70839    Purinergic receptor P2Y, G-protein--coupled 12
  *Pag1*       ENSMUSG00000027508   94212    Phosphoprotein associated with glycosphingolipid microdomains 1
  *Pde3b*      ENSMUSG00000030671   18576    Phosphodiesterase 3B, cGMP inhibited
  *Prkca*      ENSMUSG00000050965   18750    Protein kinase C, alpha
  *Prpsap2*    ENSMUSG00000020528   212627   Phosphoribosyl pyrophosphate synthetase-associated protein 2
  *Rhoh*       ENSMUSG00000029204   74734    Ras homologue family member H
  *Rilpl1*     ENSMUSG00000029392   75695    Rab interacting lysosomal protein-like 1
  *Rtn4rl1*    ENSMUSG00000045287   237847   Reticulon 4 receptor-like 1
  *Sall1*      ENSMUSG00000031665   58198    Sal-like 1 (*Drosophila*)
  *Sall3*      ENSMUSG00000024565   20689    Sal-like 3 (*Drosophila*)
  *Serpine2*   ENSMUSG00000026249   20720    Serine (or cysteine) peptidase inhibitor, clade E, member 2
  *Sgce*       ENSMUSG00000004631   20392    Sarcoglycan, epsilon
  *Slc2a5*     ENSMUSG00000028976   56485    Solute carrier family 2 (facilitated glucose transporter), member 5
  *Snx17*      ENSMUSG00000029146   266781   Sorting nexin 17
  *Sparc*      ENSMUSG00000018593   20692    Secreted acidic cysteine rich glycoprotein
  *Stard3*     ENSMUSG00000018167   59045    START domain containing 3
  *Syngr1*     ENSMUSG00000022415   20972    Synaptogyrin 1
  *Tgfa*       ENSMUSG00000029999   21802    Transforming growth factor alpha
  *Tmem119*    ENSMUSG00000054675   231633   Transmembrane protein 119
  *Tmem204*    ENSMUSG00000024168   407831   Transmembrane protein 204
  *Zbtb18*     ENSMUSG00000063659   30928    Zinc-finger and BTB domain containing 18

List of the 52 up-regulated genes identified to distinguish microglia from beMφ via the approach outlined in [Fig. 5 A](#fig5){ref-type="fig"}.

###### List of genes in the beMφ-50 signature

  Symbol        Ensembl              Entrez   Name
  ------------- -------------------- -------- -------------------------------------------------------------------------------------------
  *Abca1*       ENSMUSG00000015243   11303    ATP-binding cassette, subfamily A (ABC1), member 1
  *Arhgef10l*   ENSMUSG00000040964   72754    Rho guanine nucleotide exchange factor 10-like
  *Car9*        ENSMUSG00000028463   230099   Carbonic anhydrase 9
  *Cln6*        ENSMUSG00000032245   76524    Ceroid-lipofuscinosis, neuronal 6
  *Cxcr3*       ENSMUSG00000050232   12766    Chemokine (C-X-C motif) receptor 3
  *Cysltr2*     ENSMUSG00000033470   70086    Cysteinyl leukotriene receptor 2
  *Dclre1c*     ENSMUSG00000026648   227525   DNA cross-link repair 1C
  *Dnajb14*     ENSMUSG00000074212   70604    DnaJ heat shock protein family (Hsp40) member B14
  *Fap*         ENSMUSG00000000392   14089    Fibroblast activation protein
  *Fgf2*        ENSMUSG00000037225   14173    Fibroblast growth factor 2
  *Flt3*        ENSMUSG00000042817   14255    FMS-like tyrosine kinase 3
  *Frmd6*       ENSMUSG00000048285   319710   FERM domain containing 6
  *Fzd7*        ENSMUSG00000041075   14369    Frizzled class receptor 7
  *Galc*        ENSMUSG00000021003   14420    Galactosylceramidase
  *Gk*          ENSMUSG00000025059   14933    Glycerol kinase
  *Gpr176*      ENSMUSG00000040133   381413   G protein--coupled receptor 176
  *H2-T10*      ENSMUSG00000079491   15024    Histocompatibility 2, T region locus 10
  *Hoxb4*       ENSMUSG00000038692   15412    Homeobox B4
  *Ifnar1*      ENSMUSG00000022967   15975    Interferon (alpha and beta) receptor 1
  *Jag1*        ENSMUSG00000027276   16449    Jagged 1
  *Kcnn4*       ENSMUSG00000054342   16534    Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4
  *Lpar6*       ENSMUSG00000033446   67168    Lysophosphatidic acid receptor 6
  *Ltbp3*       ENSMUSG00000024940   16998    Latent transforming growth factor beta binding protein 3
  *Nrp1*        ENSMUSG00000025810   18186    Neuropilin 1
  *Pcgf2*       ENSMUSG00000018537   22658    Polycomb group ring finger 2
  *Pgap1*       ENSMUSG00000073678   241062   Post-GPI attachment to proteins 1
  *Pi4k2b*      ENSMUSG00000029186   67073    Phosphatidylinositol 4-kinase type 2 beta
  *Plekhg5*     ENSMUSG00000039713   269608   Pleckstrin homology domain containing, family G (with RhoGef domain) member 5
  *Pmepa1*      ENSMUSG00000038400   65112    Prostate transmembrane protein, androgen induced 1
  *Qpct*        ENSMUSG00000024084   70536    Glutaminyl-peptide cyclotransferase (glutaminyl cyclase)
  *Rap2a*       ENSMUSG00000051615   76108    RAS related protein 2a
  *Rgs1*        ENSMUSG00000026358   50778    Regulator of G-protein signaling 1
  *S1pr1*       ENSMUSG00000045092   13609    Sphingosine-1-phosphate receptor 1
  *Sesn1*       ENSMUSG00000038332   140742   Sestrin 1
  *Sestd1*      ENSMUSG00000042272   228071   SEC14 and spectrin domains 1
  *Sgsh*        ENSMUSG00000005043   27029    N-sulfoglucosamine sulfohydrolase (sulfamidase)
  *Sh3d19*      ENSMUSG00000028082   27059    SH3 domain protein D19
  *Slc26a11*    ENSMUSG00000039908   268512   Solute carrier family 26, member 11
  *Slc44a1*     ENSMUSG00000028412   100434   Solute carrier family 44, member 1
  *Slit1*       ENSMUSG00000025020   20562    Slit homologue 1 (*Drosophila*)
  *Stab1*       ENSMUSG00000042286   192187   Stabilin 1
  *Stbd1*       ENSMUSG00000047963   52331    Starch binding domain 1
  *Tlr8*        ENSMUSG00000040522   170744   Toll-like receptor 8
  *Tmem176b*    ENSMUSG00000029810   65963    Transmembrane protein 176B
  *Tnfrsf11a*   ENSMUSG00000026321   21934    Tumor necrosis factor receptor superfamily, member 11a, NF-κB activator
  *Tpst1*       ENSMUSG00000034118   22021    Protein-tyrosine sulfotransferase 1
  *Txndc16*     ENSMUSG00000021830   70561    Thioredoxin domain containing 16
  *Xylt2*       ENSMUSG00000020868   217119   Xylosyltransferase II
  *Zdhhc23*     ENSMUSG00000036304   332175   Zinc-finger, DHHC domain containing 23
  *Znrf3*       ENSMUSG00000041961   407821   Zinc and ring finger 3

List of the 50 up-regulated genes identified to distinguish beMφ from microglia via the approach outlined in [Fig. 5 A](#fig5){ref-type="fig"}.

Of note, several previously identified microglia-specific genes were included in the Mg-52 signature, such as *Cst3*, *Hexb*, *P2ry12*, and *Sall1*, and *Tmem119*. Based on this, we tested P2ry12 as a marker of microglia versus beMφs. Indeed, although both beMφs and microglia stained for Iba1 ([Fig. 5 B](#fig5){ref-type="fig"}), P2ry12 was a unique marker for microglia ([Fig. 5 C](#fig5){ref-type="fig"}).

We next evaluated the reliability of our signatures within the datasets used to generate them. As expected, all three datasets universally demonstrated enrichment of Mg-52 in microglia and enrichment of the beMφ-50 in beMφ ([Fig. 5 D](#fig5){ref-type="fig"}). In a study by [@bib54], gene clusters involved in stages of microglia development were identified. We assessed the overlap of our signatures with these microglia developmental gene clusters and found that the only substantial overlap occurred with the Mg-52 signature and the "Adult Microglia" developmental gene cluster (37/52 genes in Mg-52; [Fig. 5 E](#fig5){ref-type="fig"}). These results supported the idea that the Mg-52 signature is specific to adult microglia and that the beMφ-50 signature does not correlate to any microglia developmental programs.

To test the specificity of Mg-52 and beMφ-50 for their respective cell types, we used a competitive gene set test (CAMERA; [@bib73]). Publically available transcriptomic datasets of immune cells ([@bib33]), neurons ([@bib66]), astrocytes ([@bib66]), beMφs ([@bib12]; [Table 3](#tbl3){ref-type="table"}), and our LPS-treated beMφ data (which were not used in the generation of signatures) were used to validate the signatures. All of these datasets contain microglia samples that were used as a common reference cell in our CAMERA analysis. As expected, neither neurons nor astrocytes were enriched for beMφ-50, but microglia were enriched for the Mg-52 signature as compared with neurons and astrocytes ([Fig. 5 F](#fig5){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). Similarly, LPS-treated microglia were not enriched for beMφ-50 as compared with control microglia, whereas control microglia were enriched for Mg-52 ([Fig. 5 F](#fig5){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}).

###### List of publically available datasets used in this study

  GEO dataset   First author   Conditions                                                                                 Study type         GEO link                                                        Publication link
  ------------- -------------- ------------------------------------------------------------------------------------------ ------------------ --------------------------------------------------------------- ------------------------------------------------
  GSE68376      Bruttger       Microglia versus CNS engrafting bone marrow--derived macrophages (beMφs)                   RNA sequencing     <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68376>    <http://www.ncbi.nlm.nih.gov/pubmed/26163371>
  GSE15907      ImmGen         Microglia versus peripheral immune cells for signature validation                          Affymetrix Array   <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15907>    Multiple, see citations on GEO page
  GSE63340      Lavin          Comparison of microglia to peripheral macrophages/monocytes for generation of signatures   RNA sequencing     <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63340>    <http://www.ncbi.nlm.nih.gov/pubmed/25480296>
  GSE75246      Srinivasan     LPS-treated and control neurons/astrocytes/microglia                                       RNA sequencing     <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75246>   <https://www.ncbi.nlm.nih.gov/pubmed/27097852>
  GSE99078      Takata         iMac versus BM Mac                                                                         RNA sequencing     <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99078>   <https://www.ncbi.nlm.nih.gov/pubmed/28723550>

###### CAMERA statistics used in the validation of the Mg-52 and beMφ-50 genetic signatures

  **GEO dataset**   **Control**                  **Experimental**                      **Mg-52**            **beMφ-50**                                                                       
  ----------------- ---------------------------- ------------------------------------- -------------------- ------------------------------------------------------------ -------------------- ------------------------------------------------------------
                                                                                                                                                                                              
  GSE75246          Microglia, vehicle treated   Microglia, LPS treated                −9.18997599139088    *8.73894827192082E-20*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.960428754944643   0.336853025380644
  GSE75246          Microglia, vehicle treated   Neuron, vehicle treated               −9.28373097503757    *3.65539900363888E-20*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.6069073647106     0.108093118311235
  GSE75246          Microglia, vehicle treated   Astrocyte, vehicle treated            −8.43449685504562    *7.17579519282282E-17*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.982701094445303   0.325768448416933
  GSE75246          Microglia, LPS treated       Neuron LPS treated                    −5.703178515505      *2.3906543497579E-08*[^a^](#ttbl4n2){ref-type="table-fn"}    −1.23253311708603    0.217766916347967
  GSE75246          Microglia, LPS treated       Astrocyte, LPS treated                −3.82020514805529    *0.000267622477204*[^a^](#ttbl4n2){ref-type="table-fn"}      −0.76323460910686    0.445334000895242
  GSE75246          Neuron, vehicle treated      Neuron, LPS treated                   −2.48230960173674    0.026125771365367                                            1.03261170555403     0.30180022362708
  GSE75246          Neuron, vehicle treated      Astrocyte, vehicle treated            2.39665178928464     0.033112577014953                                            0.940103366793486    0.347177795693465
  GSE75246          Astrocyte, vehicle treated   Astrocyte, LPS treated                −0.355557598200872   0.722176280064764                                            −0.55668524588016    0.722176280064764
  GSE15907          Microglia                    SI LP macrophage                      −11.2065064200678    *9.18045352544835E-29*[^a^](#ttbl4n2){ref-type="table-fn"}   4.71522334166825     *2.43012363462998E-06*[^a^](#ttbl4n2){ref-type="table-fn"}
  GSE15907          Microglia                    Lung CD11b^+^ macrophage              −17.8986346561823    *8.2656485448573E-71*[^a^](#ttbl4n2){ref-type="table-fn"}    3.75505071435236     *0.000173778763046*[^a^](#ttbl4n2){ref-type="table-fn"}
  GSE15907          Microglia                    SI serosal macrophage                 −12.8781234055138    *1.66788609720075E-37*[^a^](#ttbl4n2){ref-type="table-fn"}   4.98232404004903     *6.33293438301929E-07*[^a^](#ttbl4n2){ref-type="table-fn"}
  GSE15907          Microglia                    Peritoneal F4/80lo macrophage         −13.8346052104306    *4.90645664168948E-43*[^a^](#ttbl4n2){ref-type="table-fn"}   1.33690258052763     0.181269070989656
  GSE15907          Microglia                    LN CD169^+^CD11c^+^ macrophage        −16.7938329111185    *1.40723697488701E-62*[^a^](#ttbl4n2){ref-type="table-fn"}   0.323384063567144    0.746407650677293
  GSE15907          Microglia                    BM macrophage                         −14.1038712769937    *1.1592597363317E-44*[^a^](#ttbl4n2){ref-type="table-fn"}    −0.91021289075231    0.362720802630218
  GSE15907          Microglia                    Medullary sinus macrophage            −16.9449218942956    *1.12872637834688E-63*[^a^](#ttbl4n2){ref-type="table-fn"}   0.394208861959158    0.693430887937153
  GSE15907          Microglia                    LN subcapsular macrophage             −16.8108255068152    *1.06072069454246E-62*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.569435569747971   0.569066737637983
  GSE15907          Microglia                    Peritoneal F4/80^hi^ macrophage       −13.2907475407257    *7.64121015322315E-40*[^a^](#ttbl4n2){ref-type="table-fn"}   1.77706541396221     0.075572099377594
  GSE15907          Microglia                    Red pulp macrophage                   −13.8968419518646    *2.07736897631509E-43*[^a^](#ttbl4n2){ref-type="table-fn"}   0.800634377157631    0.423352494668722
  GSE15907          Microglia                    Lung CD11c^+^ macrophage              −12.449942293778     *3.74528948133128E-35*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.84381236333192    0.065224715729658
  GSE15907          Microglia                    BM Ly6c^+^MHCII^−^ monocyte           −15.9185653482659    *2.03921322346964E-56*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.818538144350527   0.413059355130746
  GSE15907          Microglia                    BM Ly6c^−^MHCII^−^ monocyte           −16.995529069284     *4.82435079029921E-64*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.4980128606501     0.618480246889288
  GSE15907          Microglia                    Blood Ly6c^+^MHCII^+^ monocyte        −16.4580514220967    *3.54539257686525E-60*[^a^](#ttbl4n2){ref-type="table-fn"}   0.935598972668471    0.349490573927721
  GSE15907          Microglia                    Blood Ly6c^+^MHCII^−^ monocyte        −13.4521196565583    *8.89007050093597E-41*[^a^](#ttbl4n2){ref-type="table-fn"}   0.93218558886987     0.351251449984407
  GSE15907          Microglia                    LN Ly6c^+^MHCII^−^ monocyte           −16.8225925914844    *8.72001502349316E-63*[^a^](#ttbl4n2){ref-type="table-fn"}   1.24084625878423     0.214676554440318
  GSE15907          Microglia                    Blood Ly6c^−^MHCII^+^ monocyte        −18.884692403881     *1.39532275643974E-78*[^a^](#ttbl4n2){ref-type="table-fn"}   0.270993599010383    0.786398646520675
  GSE15907          Microglia                    Blood Ly6c^−^MHCII^−^ monocyte        −16.5767118715121    *5.08670106411122E-61*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.514869830796944   0.60664945933478
  GSE15907          Microglia                    Blood Ly6c^−^MHCII^int^ monocyte      −13.856797569651     *3.61293182305638E-43*[^a^](#ttbl4n2){ref-type="table-fn"}   0.232110933264168    0.816454138490933
  GSE15907          Microglia                    Blood neutrophil                      −12.9632371395544    *5.56623874137407E-38*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.79279030852971    0.073020996049815
  GSE15907          Microglia                    BM neutrophil                         −11.4003953949682    *1.02230860670541E-29*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.72096439038072    0.08527216840678
  GSE15907          Microglia                    Spleen CD4^+^ DC                      −13.9384560198774    *1.16689659747184E-43*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.245307707479572   0.806220606319135
  GSE15907          Microglia                    Spleen CD8^+^ DC                      −13.7057882876266    *2.87179757732365E-42*[^a^](#ttbl4n2){ref-type="table-fn"}   0.398151064886531    0.690522924468198
  GSE15907          Microglia                    Spleen CD4^−^CD8^−^CD11b^−^ DC        −15.1108056316066    *5.1513600603475E-51*[^a^](#ttbl4n2){ref-type="table-fn"}    −0.371877852772889   0.709987586561984
  GSE15907          Microglia                    Spleen CD8^+^ pDC                     −11.9560451648539    *1.54734296499501E-32*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.5330479854046     0.594006063116689
  GSE15907          Microglia                    Spleen CD8^−^ pDC                     −12.0888471854728    *3.13529730173023E-33*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.686519292990229   0.492393361276459
  GSE15907          Microglia                    Spleen CD4^−^CD8^−^CD11b^+^ DC        −16.7499579333542    *2.91605319710899E-62*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.773651602002031   0.439145647090047
  GSE15907          Microglia                    Lung CD103^+^ DC                      −12.9476715882146    *6.80692723941832E-38*[^a^](#ttbl4n2){ref-type="table-fn"}   1.56459587282508     0.117692921772633
  GSE15907          Microglia                    Lung CD11b^+^CD24^+^ DC               −14.2347565935749    *1.83032966037038E-45*[^a^](#ttbl4n2){ref-type="table-fn"}   1.79831123076597     0.072142206176879
  GSE15907          Microglia                    Liver CD103^+^ DC                     −14.59556587753      *1.0361250320237E-47*[^a^](#ttbl4n2){ref-type="table-fn"}    0.882871388829489    0.377315974859225
  GSE15907          Microglia                    Kidney CD103^−^CD11b^+^F4/80^lo^ DC   −13.3863273878228    *2.14353221609188E-40*[^a^](#ttbl4n2){ref-type="table-fn"}   1.96342185139998     0.049610489223897
  GSE15907          Microglia                    Langerhans cell                       −13.5648053990461    *1.94992734843495E-41*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.368430279415978   0.71255617554319
  GSE15907          Microglia                    Spleen follicular B cell              −11.8221570653282    *7.60363847464607E-32*[^a^](#ttbl4n2){ref-type="table-fn"}   −2.06435720774193    0.038996239349848
  GSE15907          Microglia                    Spleen MZ B cell                      −12.8680272621344    *1.89888380743561E-37*[^a^](#ttbl4n2){ref-type="table-fn"}   −2.21791907042995    0.02657112051891
  GSE15907          Microglia                    Spleen GC B cell                      −11.6270160082023    *7.5026540207794E-31*[^a^](#ttbl4n2){ref-type="table-fn"}    −2.63836018619294    0.008337012761183
  GSE15907          Microglia                    Peritoneal B1a cell                   −12.8368524481395    *2.83249315683069E-37*[^a^](#ttbl4n2){ref-type="table-fn"}   −2.25999214810576    0.023832043427742
  GSE15907          Microglia                    Peritoneal B1b cell                   −12.4704022163508    *2.90329306882604E-35*[^a^](#ttbl4n2){ref-type="table-fn"}   −2.03073615939647    0.042294469723543
  GSE15907          Microglia                    Spleen naive CD4^+^ T cell            −12.0514689371187    *4.92231507926634E-33*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.32085874766837    0.186563009465559
  GSE15907          Microglia                    Spleen naive CD8^+^ T cell            −15.632336222605     *1.79884156914574E-54*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.88247758455911    0.059785157409316
  GSE15907          Microglia                    Spleen memory CD4^+^ T cell           −12.7721168022034    *6.47878151163567E-37*[^a^](#ttbl4n2){ref-type="table-fn"}   −0.442027244316272   0.658474090360188
  GSE15907          Microglia                    Spleen memory CD8^+^ T cell           −13.5419211345285    *2.65618103458737E-41*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.33469326750991    0.181991378524863
  GSE15907          Microglia                    Spleen T regulatory cell              −15.4254434586749    *4.36485159999069E-53*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.26238816488991    0.206823310056597
  GSE15907          Microglia                    Spleen natural killer cell            −15.8677797159762    *4.54101007200768E-56*[^a^](#ttbl4n2){ref-type="table-fn"}   −1.28565291148151    0.198578545975841
  GSE68376          Microglia                    beMφ                                  −10.6110235228595    *6.8924083456567E-26*[^a^](#ttbl4n2){ref-type="table-fn"}    6.56936921593136     *5.25863738290986E-11*[^a^](#ttbl4n2){ref-type="table-fn"}
  GSE108575         Microglia, LPS treated       beMφ, LPS treated                     −7.64393242343623    *2.23315767992962E-14*[^a^](#ttbl4n2){ref-type="table-fn"}   8.126057045216       *9.55133453377967E-16*[^a^](#ttbl4n2){ref-type="table-fn"}
  GSE99078          iMac, day 0                  BM Mac, day 0                         −2.27409571243689    0.022973398251917                                            4.85289376959958     *2.45636395979254E-06*[^a^](#ttbl4n2){ref-type="table-fn"}
  GSE99078          iMac, day 3                  BM Mac, day 3                         −5.60231923708091    *4.29964257929522E-08*[^a^](#ttbl4n2){ref-type="table-fn"}   1.34724285505885     0.177921083688115
  GSE99078          iMac, day 6                  BM Mac, day 6                         −5.17686685222183    *4.56742989186354E-07*[^a^](#ttbl4n2){ref-type="table-fn"}   3.23262604923775     0.001229061186423
  GSE99078          iMac, day 12                 BM Mac, day 12                        −4.26858897016626    *2.48966525049818E-05*[^a^](#ttbl4n2){ref-type="table-fn"}   4.21696975941865     *2.48966525049818E-05*[^a^](#ttbl4n2){ref-type="table-fn"}

Publically available transcriptomic datasets and transcriptomic data generated in the current study were used to assess for enrichment of Mg-52 and beMφ-50 gene signatures. CAMERA analysis was performed as described in Materials and methods.

Significance threshold FDR \<0.001.

Likewise, the Mg-52 signature was enriched in microglia compared with all immune cell types tested from the publically available Immgen microarray dataset ([@bib33]), again supporting the fidelity of this signature for the detection of microglia versus nonmicroglia ([Fig. 5, F and G](#fig5){ref-type="fig"}; and [Table 4](#tbl4){ref-type="table"}). However, three peripheral immune cell types were significantly enriched for beMφ-50: small intestine serosal macrophages, lung CD11b^+^ macrophages, and small intestine lamina propria macrophages ([Fig. 5, F and G](#fig5){ref-type="fig"}; and [Table 4](#tbl4){ref-type="table"}). Interestingly, all three of these are monocyte-derived macrophages, providing further evidence of a monocyte origin for beMφ.

Importantly, there was strong enrichment for beMφ-50 in beMφ transcriptomes generated in another laboratory ([@bib12]; [Fig. 5, F and H](#fig5){ref-type="fig"}; and [Table 4](#tbl4){ref-type="table"}). We also observed strong enrichment for beMφ-50 in LPS-treated beMφ ([Fig. 5, F and I](#fig5){ref-type="fig"}; and [Table 4](#tbl4){ref-type="table"}), confirming our initial observation that beMφs and microglia have core genes that can be used to define each cell type regardless of a strong stimulus.

Finally, we used our signatures to interrogate recently published data that purports to have generated induced pluripotent stem cell--derived microglia-like cells (iMacs; [@bib67]). When CAMERA analysis was applied to RNA-sequencing data from iMacs versus bone marrow--derived macrophages (BM Macs) over the course of an in vitro co-culture with neurons, we found that Mg-52 became significantly enriched in iMac by day 3 of co-culture, and remained enriched through day 12 ([Fig. 5 J](#fig5){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). By comparison, beMφ-50 was enriched in BM Mac on days 0 and 12 ([Fig. 5 J](#fig5){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). These results supported the conclusions of [@bib67] that they had generated microglia-like cells in vitro.

Overall, these data confirmed that Mg-52 and beMφ-50 represent core signatures that may be used to define and identify microglia and beMφs in a direct comparison. In addition, the fact that each cell type has a distinct core genetic program lends strong evidence that beMφ indeed represent an independent type of macrophage that could have a long-lived presence and unique functional implications in the CNS.

Discussion {#s07}
==========

The role of peripherally derived engrafting macrophages in the CNS has long been a subject of scientific interest and debate ([@bib58]; [@bib43]). In this work, we investigated several outstanding questions regarding these enigmatic cells. First, using a genetic model of chronic partial microglia deficiency, we showed that persistent loss of microglia and their inability to repopulate the niche is sufficient to induce beMφ engraftment into the CNS (i.e., in the absence of irradiation). Second, we demonstrated that beMφs do not alter brain function as measured by a wide array of behavioral tests. Third, we found that beMφs maintain a unique transcriptional and functional identity in three different models of beMφ engraftment. Fourth, we generated functional genetic signatures capable of detecting either beMφs (beMφ-50) or microglia (Mg-52) in a direct comparison. Finally, we validated their ability to specifically detect microglia (Mg-52) or beMφs and other monocyte-derived macrophages (beMφ-50) in the datasets that we generated and in other, publically available transcriptomic datasets.

It was previously unclear as to whether or not beMφ would eventually differentiate into bona fide microglia, and thereby take on the exact physiological roles of microglia in the CNS. Here, we have provided evidence to suggest that beMφs are in fact a unique cell type and, although capable of taking up long-term residence in the CNS, maintain a unique transcriptional and functional identity. This may help to explain the reported therapeutic roles for beMφs ([@bib71]; [@bib41], [@bib42]; [@bib56]; [@bib17]; [@bib21]; [@bib35]) and suggests that beMφs may not only "replace" dysfunctional microglia but also in fact provide unique therapeutic benefits based on their unique identity and functional profile. Further, the fact that chronic microglia depletion (along with the inability of the remaining microglia to proliferate and refill the niche) is sufficient to drive beMφ engraftment into the brain gives hope that in the future, it may be possible to use radiation-free conditioning regimens to achieve substantial beMφ engraftment in patients. Such an approach would focus on specifically targeting microglia proliferation while leaving the circulating monocyte pool intact. This may be a challenging task, because both microglia and other myeloid cells primarily use Csf1 signaling for proliferation and survival; alternative targets for specific microglia depletion would likely be necessary in the clinical context. It is also encouraging that we did not find any substantial behavioral abnormalities upon beMφ engraftment, as this could be a significant concern if such high levels of beMφ engraftment were achieved in patients.

Our models demonstrate that beMφ could replace microglia only when microglia are impaired in their ability to repopulate the niche, without the need for irradiation, inflammation, or BBB disruption. It is important to note that previously published data demonstrating the ability of microglia to self-repopulate are not refuted by our findings ([@bib23]; [@bib12]; [@bib36]). On the contrary, we support the concept that under most physiological circumstances microglia will repopulate the niche through self-renewal. It is conceivable, however, that during the long lifespan of a human, beMφs may engraft into a brain under certain pathological conditions (in which microglia self-renewal is affected), changing the myeloid niche of the brain. Our data also suggest that impairment of microglia self-renewal is likely one of the primary effects of irradiation-induced repopulation of the brain by beMφs.

Together, our findings demonstrate that peripherally derived CNS macrophages are a unique cell type capable of replacing microglia in the context of microglia deficiency without irradiation. These findings reframe the identity of beMφs and firmly place them as an independent class of brain macrophage. Our findings may be therapeutically exploited in the future to achieve beMφ engraftment without irradiation.

Materials and methods {#s08}
=====================

Animal experiment approval {#s09}
--------------------------

All experiments were approved by the Institutional Animal Care and Use Committee of the University of Virginia.

Mice {#s10}
----

Mice were initially purchased from The Jackson Laboratory and subsequently maintained and bred in-house under standard housing conditions (12 h light/dark cycle and fed ad libitum). All mice were on a C57BL/6J background, and both males and females were used unless stated otherwise. Strains used were C57BL/6J, C57BL/6-Tg(UBC-GFP)30Scha/J, B6.129P2(C)-Cx3cr1^tm2.1(cre/ERT2)Jung^/J, and B6.Cg-Csf1r^tm1.2Jwp^/J. *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice were generated by breeding *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice with *Cx3cr1^+/+^::Csf1r^Flox/Flox^* mice. For experiments using tamoxifen, mice were fed TD.130856 at 250 mg/kg diet (purchased from Harlan) starting at 4 wk after birth or as otherwise specified in figures. Experimental groups were blinded before beginning the experiment and remained blinded until the end.

Irradiation and BMT {#s11}
-------------------

Mice were γ irradiated with a lethal dose of 1,000 rad. 4 h after irradiation, mice were intravenously injected with 5 × 10^6^ bone marrow cells. Mice were given water supplemented with trimethoprim-sulfamethoxazole for 2 wk and monitored daily for the first 4 d. A lead shield was placed over the head during irradiation in some experiments, as indicated.

Tissue collection {#s12}
-----------------

Mice were euthanized with Euthasol and transcardially perfused with 0.01 M PBS containing 5 U/ml heparin. Blood was collected from the retinal artery after removing the eye and placed in heparinized tubes. For immunohistochemistry, brains were carefully removed and dropped fixed in 4% paraformaldehyde for 48 h. Brains were then washed with PBS and stored at 4°C until further processing. For isolating cells, brains were harvested and immediately processed as described below. Intestinal cell suspensions were prepared as previously described ([@bib19]). In brief, the entire length of the small intestine was excised and opened longitudinally. Luminal contents were washed in Ca/Mg-free PBS, chopped in 2.5-cm pieces, and placed in conical tubes containing 30 ml HBSS, 5% FBS, and 2 mM EDTA. The tubes were shaken at 37°C and 250 rpm for 20 min, after which the intestines were strained through a nylon mesh and washed again under the same conditions. After the last wash, the intestines were transferred into 20 ml HBSS containing 900 U/ml Collagenase VIII (Sigma) and 40 U/ml DNase-I (Sigma) and then shaken for 15 min at 200 rpm to digest. After the incubation, the tubes were vortexed thoroughly and the resulting cell suspension passed through 70-µm cell strainers into clean tubes. The cells were washed twice with cold HBSS, 5% FBS, and 2 mM EDTA and centrifuged at 4°C, 425 relative centrifugal force (RCF), for 5 min. After the last wash, the supernatant was decanted and the pellet was resuspended in FACS buffer containing 0.01 M PBS, 1% BSA, 2 mM EDTA, and 0.1% sodium azide and prepared for FACS analysis.

Flow cytometry {#s13}
--------------

After tissue collection (as described above), cells were incubated with flow cytometry antibodies at 4°C for 30 min in a total volume of 200 µl of flow cytometry buffer (PBS containing 0.1% sodium azide and 1% BSA), washed with 5 ml flow cytometry buffer, pelleted at 300 RCF, decanted, and analyzed on a Gallios flow cytometer (Beckman Coulter). Antibodies were purchased from BD PharMingen except for CD115 (BioLegend).

Immunohistochemistry {#s14}
--------------------

Brains were collected as described above and cryoprotected in 30% sucrose. After freezing in optimum cutting temperature compound (Sakura Finetek), 40-µM sections were cut on a cryostat (Leica). Floating sections were stored in PBS containing Azide (0.02%) until further processing. For immunohistochemistry, brain sections were permeabilized with PBS containing 0.5% Triton X-100 and then blocked with 10% chicken serum in PBS containing 0.05% Triton X-100 for 1 h. Sections were then incubated overnight with primary antibody in PBS containing 2% chicken serum. Primary antibodies included rabbit anti-GFP (1:1,000; Abcam), goat anti-Iba1 (1:300; Abcam), rabbit anti-Iba1 (1:300; Wako), rabbit-anti Ki67 (1:500; Abcam), and rabbit anti-P2ry12 (1:10,000; gift from O. Butovsky, Ann Romney Center for Neurologic Diseases, Brigham and Women\'s Hospital, Harvard Medical School, Boston, MA). After incubating primary antibody, sections were washed three times and then incubated with fluorescently conjugated secondary antibodies (1:1,000) in PBS containing 0.05% Triton X-100 and 2% chicken serum for 1 h. Sections were then washed three times with PBS containing 0.05% Triton X-100. DAPI was added to the second wash to stain DNA containing nuclei. Sections were then mounted on microscope slides with Aquamount. All images were collected on a Leica SP8 confocal microscope or Leica wide-field microscope.

BrdU proliferation assay {#s15}
------------------------

BrdU injection and analysis were performed as previously described ([@bib53]). In brief, mice were injected twice (i.p.) with 50 mg/mg BrdU, with 2 h between each injection. Brains were analyzed by immunohistochemistry 24 h after the last BrdU injection.

Cell sorting {#s16}
------------

To FACS sort microglia and beMφ, brains were collected after euthanization and systemic perfusion with PBS, and then meninges were removed. Brains were physically minced and incubated in a 15-ml tube in 5 ml HBSS containing Mg and Ca, 2 mg/ml papain, 50 U/ml DNASE-I (Sigma), and Glutamax (Invitrogen) at 37°C for 15 min. After gentle trituration, the brains were incubated at 37°C for an additional 15 min, triturated, incubated at 37°C for an additional 15 min, and triturated a third time. After this, the tubes were filled with DMEM/F12 containing 10% FBS and filtered through a 70-µM cell strainer. Cells were pelleted at 300 RCF and sorted as follows. Cells were incubated with CD11b^+^ microglia magnetic selection beads according to manufacturer's protocol (Miltenyi). Cells were then positively selected by AutoMACS and used for downstream applications or FACS sorted by gating on live cells by DAPI exclusion (DAPI-negative cells, high side scatter exclusion, singlet events, CD45^Lo^, CD11b^+^, and either GFP^−^ \[microglia\] or GFP^+^ \[beMφs\]). Monocytes were isolated from bone marrow using mouse bone marrow monocyte selection beads and sorted on an LS magnetic columns according to the manufacturer's protocol (Miltenyi). Sorted monocytes were at least 95% pure monocytes (CD11b^+^Ly6C^Hi^CD115^+^) by flow cytometry.

RNA sequencing and quantitative RT-PCR {#s17}
--------------------------------------

RNA was isolated from FACS-sorted microglia using an RNeasy mini kit (QIAGEN). Each sample used for RNA-sequencing was pooled from three or four total mice per sample. For quantitative RT-PCR, cDNA was generated using High Capacity cDNA kit (Applied Biosystems) and *Csf1r* gene expression was analyzed with the Mm00432691_m1 TaqMan Gene Expression assay. For RNA sequencing, all postprocessing (including linear RNA amplification and cDNA library generation) and sequencing was performed by Hudson Alpha Genomic Services Laboratory.

Evans blue BBB permeability assay {#s18}
---------------------------------

To test for BBB permeability, mice were injected i.p. with Evans blue (13.3 µl/g of a 2% Evans blue solution dissolved in PBS) and samples were collected 1 h after injection. Mice were euthanized by Euthasol, perfused with ice cold PBS, and brains were removed. One half of each brain was homogenized in 1ml of PBS and mixed with one volume of 50% trichloroacetic acid, then incubated overnight at 4°C to precipitate out proteins and other particulates. Samples were centrifuged at 15,000 *g* for 30 min, 4°C. Supernatants were analyzed by 96-well plate reader at 620 nm (Multiskan FC; Fisher Scientific), and a standard curve was generated using known concentrations of Evans blue dye in PBS mixed 1:1 with 50% trichloroacetic acid.

Parabiosis {#s19}
----------

Surgery for parabiosis was performed as previously described ([@bib59]). Female UBC-GFP mice were paired to *Cx3cr1^CreER/+^::Csf1r^Flox/Flox^* mice or Cre-negative controls matched for age, sex, and weight. After parabiosis surgery, mice were allowed 3 wk to recover before a 12-wk tamoxifen treatment.

Behavior {#s20}
--------

Behavioral testing was performed as previously described ([@bib59]; [@bib25]). Before all behavior testing, mice were acclimated to the testing room for 1 h. Testing schedules were balanced for genotype and the observer was blinded to all conditions. Mazes were cleaned with 70% ethanol between trials and all behavioral assays were performed during the light hours avoiding 1 h after and before the lights turned on and off.

### Plus maze {#s21}

Mice were place into the center hub of the plus maze and were free to explore for 5 min. Movement was calculated with TopScan (CleverSys), and data were represented as percentage of time spent in the open arms during the 5-min trial.

### Open field {#s22}

Mice were placed into an open field (35 cm × 35 cm) and were free to explore for 15 min. Movement was monitored via TopScan, and data were represented as percentage of time spent in the center of the box (23 cm × 23 cm) during the 15-min trial.

### Sociability {#s23}

Social behavior was tested using the three-chamber assay. Mice were placed into the center chamber of a three-chamber social box and were free to explore all three rooms for 10 min per phase. For the habituation phase, empty wire cages (Spectrum Diversified Designs) were placed in the two outer rooms. After the initial habituation phase, the mice were returned to the center room for the social phase, where a novel mouse was placed under one cup (8--10-wk-old male habituated to the cup) and a novel object was placed under the other cup. Tracking was scored with TopScan, and time spent investigating around each cup was quantified.

### Rotarod {#s24}

Motor behavior was tested with an accelerated rotarod (MedAssociates). Mice were placed on an accelerating rotarod that accelerated from 4.0 to 40 rpm over 5 min. The latency of the mouse to fall off the rod was monitored via infrared beams. Mice were given six trials with a 4-h intertrial interval between trials 3 and 4.

### Morris water maze {#s25}

Cognitive function was tested with the water maze. For the acquisition phase, mice were placed in a 100-cm pool of opaque water with a hidden platform 1 cm under the surface. Mice were given three trials per day (maximum of 60 s) to find the platform with 30 min between each trial. This was repeated for 4 d. On the fifth day, for the probe trial, the platform was removed and mice were given 60 s to explore the maze. Video tracking of movement was performed with an EthoVision tracking system. For the acquisition phase, data were represented as latency to reach the platform. For the probe trial, data were represented as time spent in the quadrant that previously contained the platform.

Laser-burn injury {#s26}
-----------------

Brain macrophages were imaged by multiphoton microscopy. To target microglia, *Cx3cr1^CreER/+^::Ai6* were irradiated with head shielding and given bone marrow from a wild-type donor mouse. To target beMφ, wild-type mice were irradiated and given bone marrow from a *Cx3cr1^GFP/+^* donor mouse. After 4 wk of recovery, mice were fed tamoxifen for 4 wk to pulse-label macrophages and then placed back on normal chow. After 4 wk on normal chow, all mice were fed PLX5622 for 2 wk to clear out the brain macrophage pool and allowed to recover for 6 wk before imaging. For imaging, mice were anesthetized with ketamine/xylene (i.p.). Two-photon laser injury was performed by focusing a two-photon laser beam in the superficial layer of the cortex (∼50 µm deep) through a thinned intact skull as previously described ([@bib20]). In brief, a 780-nm two-photon laser (Chameleon Ultra II tunable Ti:Sapphire laser; Coherent) with a laser power of 60 to 80 mW was applied to a region of interest of 20 µm of diameter for ∼30 s (the efficiency of the injury was visualized by the bright autofluorescence sphere in the region of interest). The area was imaged for 30 min before the laser injury and 30 min after laser injury. Images were acquired using a ×25 water-immersion objective with 0.95 NA and external HyD nondescanned detectors (Leica). Four-dimensional imaging data were collected by obtaining images from the x, y, and z planes over time.

Image analysis {#s27}
--------------

Automated image analysis algorithms were developed and implemented in the Virginia Image and Video Analysis laboratory (Acton). The software was written in the MATLAB (MathWorks) environment.

### Process detection {#s28}

Microglia and engrafted macrophage processes were detected from the images using area morphology implemented via connected filters ([@bib2]; [@bib1]; [@bib3]). Such connected filters have advantages over traditional filters in that they are edge preserving and do not depend on binarized versions of the image. The processes were detected that had a two-dimensional area (observed via maximum intensity projection) within a range of 15 to 75 µm^2^ and sufficient contrast with the background (\>4% of intensity range). The positions of the processes were recorded by computing the region centroids.

### Process tracking {#s29}

Individual process locations were tracked temporally from frame to frame by finding a correspondence between detections (Scott Thomas Acton, 2006). The correspondence was determined by spatial proximity, consistency in direction of motion, and similarity in size. Group motion (and corresponding velocity) of the processes was computed using a dynamic Sholl analysis. The Sholl diagram was centered at the center of the burn site and consisted of five annuli of ring width of 17 µm. Groups of processes were tracked (in maximum intensity projection images) from the time of maximum population in the fifth annulus to the time of maximum population (of detected processes) in the third annulus (which was just outside the perimeter of the burn). This group tracking provided an overall speed computation that was robust to false positives and missed detections in the process detection task.

LPS challenge {#s30}
-------------

To determine transcriptional and morphological changes of microglia and beMφs to an insult, mice were given a peripheral LPS challenge. Mice were first irradiated and given BMT with UBC-GFP bone marrow. To target microglia, head shielding was applied during irradiation in some mice. After 1 wk of recovery, mice were treated with PLX 5622 for 2 wk to deplete the brain macrophage niche and then placed on standard chow for 6 wk. Mice were injected with 50 µg LPS or saline (i.p.). 6 h later, brains were removed and macrophages sorted by MACS on CD11b beads as described above.

RNA-sequencing and functional analysis {#s31}
--------------------------------------

The Gene Expression Omnibus (GEO) accession numbers for RNA-sequencing data generated for this publication are [GSE84819](GSE84819), [GSE108569](GSE108569), and [GSE108575](GSE108575). All other previously published datasets used in this paper are listed with GEO under the accession numbers shown in [Table 3](#tbl3){ref-type="table"} ([GSE68376](GSE68376), [GSE15907](GSE15907), [GSE63340](GSE63340), [GSE75246](GSE75246), and [GSE99078](GSE99078)). The raw sequencing reads (FASTQ files) went through two stages of preprocessing to remove low-quality reads and bases. First, they were chastity filtered, which removes any clusters that have a higher than expected intensity of the called base compared with other bases. They were then trimmed with Trimmomatic ([@bib10]) to remove low-quality bases (minimum read length after trimming, 36). After preprocessing, the quality of the reads was evaluated using FastQC ([@bib7]), and after passing quality control were aligned to the UCSC mm9 genome ([@bib32]) using the splice-aware read aligner STAR ([@bib22]). The quality of the alignments was next assessed by SAMStat ([@bib44]), and any low-quality alignments were removed with samtools ([@bib50]; MAPQ \<10). Next, the number of reads aligning to each gene was quantified with HTSeq ([@bib6]), and then the Bioconductor package ([@bib52]). DESeq2 was used to normalize the raw counts, perform exploratory analysis (e.g., PCA), and DE analysis. Before DE analysis of the BMT/PLX dataset, surrogate variable analysis ([@bib47]) was used to identify and adjust for latent sources of unwanted variation as implemented in the sva package ([@bib48]). The p-values from the DE analysis were corrected for multiple hypothesis testing with the Benjamini--Hochberg false discovery rate (FDR) procedure. Heatmaps were generated with the R package pheatmap ([@bib40]), and UpSet plots ([@bib49]) were created with the R package UpSetR ([@bib27]). The functional terms enriched in beMφs and microglia for our RNA-sequencing datasets were determined with GSVA ([@bib31]). The gene sets used for this analysis were from the GOBP ([@bib8]; [@bib68]).

Microarray analysis {#s32}
-------------------

All of the microarrays were analyzed using a combination of the affy ([@bib26]), oligo ([@bib16]), and limma ([@bib60]) packages from Bioconductor. For the Affymetrix arrays, the expression values for each probe set were extracted using the robust multichip average (RMA) methodology ([@bib37]). For the Agilent arrays, the probes were background corrected using a normal exponential convolution model (as implemented in limma; [@bib65]) and quantile normalized. Replicate probes were summarized using the mean.

Signature creation {#s33}
------------------

To create the Mg-52 signature, we first identified the differentially up-regulated genes in microglia versus beMφs in all three of the Kipnis datasets: the genetic model, traditional BMT, and BMT/PLX RNA sequencing. To be called significant, a gene needed to have a fold change \>1.5 and a corrected p-value \<0.05. These criteria for significance were used to identify all differentially expressed genes hereafter. Next, we identified the differentially up-regulated genes in microglia versus peripheral myeloid cell types (nine cell types in total) from the Lavin RNA-sequencing dataset ([@bib45]). The cell types in this dataset were peritoneal Mφ, small intestine Mφ, large intestine Mφ, monocytes, Kupffer Mφ, red pulp Mφ, alveolar Mφ, and neutrophils. The Mg-52 signature was defined as the 52 genes that were (a) up-regulated in microglia in all three of the Kipnis datasets, (b) up-regulated in eight out of nine microglia versus peripheral myeloid cell comparisons from the Lavin dataset, and (c) included in a gene set that was functionally enriched in microglia in at least one of the Kipnis datasets. To create the beMφ-50 signature, we first identified the differentially up-regulated genes in beMφ versus microglia in all three of the Kipnis datasets and the differentially up-regulated genes in the nine myeloid cell types versus microglia in the Lavin RNA-sequencing dataset. The beMφ-52 signature was defined as the 50 genes that were (a) up-regulated in beMφ in all three of the Kipnis datasets, (b) not up-regulated in the peripheral myeloid cells from the Lavin dataset, and (c) included in a gene set that was functionally enriched in beMφ in at least one of the Kipnis datasets.

Signature detection {#s34}
-------------------

The signatures were detected in the various transcriptomic datasets using CAMERA ([@bib73]; part of the limma package). The intergene correlation was set to 0.01. To use CAMERA with the RNA sequencing data, the raw counts needed to be transformed and normalized with the voom function ([@bib46]). This was not necessary for the microarray data. CAMERA returns both a test statistic and an FDR-corrected p-value. The test statistic was used as an enrichment score, with larger values of the statistic corresponding to a greater enrichment of the signature. To ensure the fidelity of the signature detection, we used a stringent corrected p-value threshold of 1E-3.

Online supplemental material {#s35}
----------------------------

Fig. S1 shows that Cx3cr1-expressing resident myeloid cells in the periphery are depleted in *Cx3cr1^CreER/+^::Csf1r^flox/flox^* mice fed tamoxifen. Fig. S2 shows data supporting [Fig. 1](#fig1){ref-type="fig"}. Fig. S3 demonstrates engraftment of beMφs in *Cx3cr1^CreER/+^::Csf1r^flox/flox^* mice with or without head shielding and BMT. Table S1 shows DE analyses of RNA-sequencing data comparing beMφs and microglia. Table S2 shows functional analysis of beMφs and microglia.
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======================

###### Supplemental Materials (PDF)

###### Tables S1 and S2 (ZIP)

We would like to thank all the members of the J. Kipnis laboratory for their valuable comments during multiple discussions of this work. We thank Anita Impagliazzo for the artwork (graphical abstract).

This work was supported by grants from the National Institutes of Health (AG034113 and NS081026 to J. Kipnis; T32-AI007496 to A.J. Filiano; and 5F30AI109984 to J.C. Cronk) and the Hartwell Foundation (to A.J. Filiano).

The authors declare no competing financial interests.

Author contributions: J.C. Cronk designed and performed experiments and wrote the manuscript. A.J. Filiano designed and performed experiments and wrote the manuscript. A. Louveau helped with experimental design and performed experiments. I. Marin designed and performed experiments related to intestinal macrophages. R. Marsh assisted with experiments involving flow cytometry and image analysis. E. Ji assisted with experiments involving flow cytometry and image analysis. D.H. Goldman performed experiments related to live imaging. I. Smirnov performed most surgeries. N. Geraci designed and performed bioinformatic analysis. S. Acton designed analysis related to live imaging. C.C. Overall designed, performed, and oversaw bioinformatic analysis and wrote the manuscript. J. Kipnis oversaw the project, designed experiments, and wrote the manuscript.

[^1]: J.C. Cronk and A.J. Filiano contributed equally to this paper.

[^2]: A.J. Filiano's present address is Dept. of Neurosurgery, Marcus Center for Cellular Cures, Duke University, Durham, NC.
